Current practice and barriers of mesh-assisted implant-based breast reconstruction in China: A nationwide cross-sectional survey of 110 hospitals

Guo, Rong; Li, Lun; Su, Yonghui; Xiu, Bingqiu; Zhang, Qi; Wang, Jia; Chi, Weiru; Yang, Benlong; Zhang, Yingying; Cao, A-Yong; Shao, Zhimin; Wu, Jiong

doi:10.1016/j.ejso.2019.09.001

Cited by 7 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18,19 Breast cancer molecular subtypes were classified as Luminal A, Luminal B HER2-positive, Luminal B HER2-negative, HER2-enriched, and triple negative. 20 The Miller and Payne grade (MPG) was used to determine the histological response. 21 Response rates were defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.…”

Section: Classification Standard and Response Evaluationmentioning

confidence: 99%

<p>Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator</p>

Chen¹,

Kong²,

Wang³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background and Objective: Systemic inflammation response index (SIRI=N×M/L), based on neutrophil (N), monocyte (M), and lymphocyte (L) counts, is used to predict the survival of patients with malignant tumors and can fully evaluate the balance between host immune and inflammatory condition. The present study is aimed to evaluate the potential prognostic significance of SIRI in patients with breast cancer undergoing neoadjuvant chemotherapy. Subjects and Methods: A total of 262 breast cancer patients treated with neoadjuvant chemotherapy were enrolled in this retrospective study. The optimal cutoff value of SIRI by receiver operating characteristic curve stratified patients into low SIRI (<0.85×10 9 /L) group and high SIRI (≥0.85×10 9 /L) group. The associations between breast cancer and clinicopathological variables by SIRI were determined by chi-square test or Fisher's exact test. Kaplan-Meier plots and log-rank test were used to evaluate the clinical outcomes of disease-free survival (DFS) and overall survival (OS). Univariate and multivariate Cox proportional hazards regression models were used to analyze the prognostic value of SIRI. The toxicity of neoadjuvant chemotherapy was evaluated by the National Cancer Institute Common Toxicity Criteria (NCICTC). Results: The results were shown that SIRI had prognostic significance by optimal cutoff value of 0.85×10 9 /L on DFS and OS in univariate and multivariate Cox regression survival analyses. Compared with patients who had high SIRI, patients with low SIRI had longer DFS and OS (41.27 vs 30.45 months, HR: 1.694, 95% CI: 1.128-2.543, P=0.011; 52.86 vs 45.75 months, HR: 1.288, 95% CI: 0.781-3.124, P=0.002, respectively). The patients with low SIRI had better 3-, 5-, and 10-year rates of DFS and OS than those with high SIRI. The common toxicities after neoadjuvant chemotherapy were hematologic and gastrointestinal reaction, and the SIRI had no significance on toxicities of all enrolled patients, excepted diarrhea. In patients without neural invasion, those with low SIRI had better prognosis and lower recurrence rates than those with high SIRI.Conclusion: Pretreatment SIRI with the advantage of repeatable, convenient, and non-invasive is a useful prognostic indicator for breast cancer patients who received neoadjuvant chemotherapy and is a promising biomarker for breast cancer on treatment strategy decisions.

show abstract

Section: Classification Standard and Response Evaluationmentioning

confidence: 99%

<p>Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator</p>

Chen¹,

Kong²,

Wang³

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…According to a survey on the breast surgery situation across hospitals in China,20 there were about 85 772 patients who received mastectomies or BCS from 110 hospitals in 2017. About 10.7% of patients underwent BR and 8.8% underwent OBCS.…”

Section: Methods and Analysismentioning

confidence: 99%

Chinese multicentre prospective registry of breast cancer patient-reported outcome-reconstruction and oncoplastic cohort (PRO-ROC): a study protocol

Yang

et al. 2019

BMJ Open

View full text Add to dashboard Cite

IntroductionAvailable patient-reported outcome (PRO) studies are mainly from single institution or of small sample size, and the variations across hospitals and regions were not fully analysed. A multicentre, prospective, patient-reported outcome-reconstruction and oncoplastic cohort (PRO-ROC) will be planned to assess the PROs of Chinese patients with breast cancer who will undergo breast reconstruction (BR) or oncoplastic breast-conserving surgery (OBCS).Methods and analysisThe inclusion criteria are female patients with breast cancer aged >18 years old who will undergo BR or OBCS. This cohort will include at least 10 000 consecutive patients (about 5000 patients who will undergo BR and 5000 patients who will undergo OBCS). The exposures were surgery types: BR and OBCS regardless of the techniques and materials used. The primary endpoint will be PROs, which include BREAST-Q and quality of life (European Organisation for Research and Treatment (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and EORTC QoL Breast Cancer-specific version (QLQ-BR23)). All patients will be followed up to 24 months after operations. All data will be prospectively collected using an app software. Data will be analysed using SPSS and Stata software.Ethics and disseminationThis study follows the Helsinki Declaration. All patients will be asked to sign an informed consent before enrolment. The results of this study will be presented at national and international meetings and published in a scientific peer-reviewed journal.Trial registration numberNCT04030845.

show abstract

“…Синтетические сетки дешевле, чем АДМ, безопасны, а эстетические результаты при их примененииулучшение проекции субмаммарной складки, формы и проекции нижнего полюса -сопоставимы с таковыми при применении АДМ [27][28][29][30][31].…”

Section: опухоли женской репродуктивной системы Tumors Of Female Repr...unclassified

The influence of synthetic and biologic matrices on the choice of the implant plane during breast reconstruction. The modern state of the problem

Baychorov

Zikiryakhodzhaev

Исмагилов

et al. 2022

Opuholi ženskoj reproduktivnoj sistemy

View full text Add to dashboard Cite

Immediately after silicone implants were described, the technique of prepectoral implant placement dominated in breast reconstructive surgery. However, this plane soon had to be abandoned due to the high frequency of complications, such as infection, capsular contracture, explantation. For these reasons, surgeons soon had to switch to the subpectoral plane. Several decades later, thanks to the discovery of synthetic and biological meshes, surgeons returned to the prepectoral plane, but at a technically new level.The purpose of this review was to analyze the role of biological and synthetic matrices as factors influencing the choice of the implant plane in one-stage breast reconstruction.

show abstract

Current practice and barriers of mesh-assisted implant-based breast reconstruction in China: A nationwide cross-sectional survey of 110 hospitals

Cited by 7 publications

References 23 publications

<p>Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator</p>

<p>Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator</p>

Chinese multicentre prospective registry of breast cancer patient-reported outcome-reconstruction and oncoplastic cohort (PRO-ROC): a study protocol

The influence of synthetic and biologic matrices on the choice of the implant plane during breast reconstruction. The modern state of the problem

Contact Info

Product

Resources

About